OR-NIKE
11.3.2019 17:43:09 CET | Business Wire | Press release
Today, more than 28 of the world’s top female footballers joined Nike (NYSE:NKE) in Paris to unveil 14 National Team Collections for this summer’s tournament in France. Record-breaking gymnast Simone Biles, champion fencer Ibtihaj Muhammad, two-time Grand Slam winner Li Na and other elite athletes also joined Nike in highlighting new partnerships to champion women and girls in sport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005652/en/
“We believe this summer can be another turning point for the growth of women’s football,” said NIKE, Inc. Chairman, President and CEO Mark Parker. “And our bigger ambition is for that energy and participation to extend into all sports. Nike’s commitment is to continue our leading support of competitive athletes, invest in the next generation at the grassroots level and deliver more innovative and compelling product design for women.”
At the historic Palais Brongniart, Nike revealed an array of future-forward women’s innovation. Design for the 14 National Team Kits began with gathering detailed input on fit from professional footballers, followed by 4D scanning and motion capture in the Nike Sports Research Lab. Echoing this focus on women’s-specific precision engineering is Nike’s Spring/Summer 2019 high-performance bra collection, which was also on display at the event. Beyond innovations in fit, the National Team Kits reflect Nike’s continued commitment to being the world’s most sustainable sports brand, with each 2019 Nike Kit constructed from at least 12 recycled plastic bottles. Since 2010, Nike has diverted more than 6 billion plastic bottles from landfills through sustainable product design.
At the event, Nike also announced a new three-year partnership with UEFA Women’s Football, building on its support of elite footballers from North America to China, and its support of standout female athletes worldwide. In basketball, Nike is partnering with the WNBA, FIBA and the Chinese Basketball Association to grow the women’s game. Meanwhile, at the collegiate level, Nike is partnering with more than 200 universities across the U.S. to support more than 25,000 top female athletes across multiple sports.
At the grassroots level, Nike is addressing barriers to girls’ participation in sport through new community partnerships and access to products to help girls play with confidence. In Paris, Nike is partnering with Sport dans la Ville to train female coaches and engage girls through sports ranging from football and boxing to tennis and dance. Globally, Nike is collaborating with Women Win and Gurls Talk to support rising female coaches who are inspiring the next generation of girls to be active. And from London to Los Angeles, and Beijing to Buenos Aires, Nike is piloting a program to provide products such as the Nike Pro Hijab and Nike Classic Sports Bra to girls in need through schools and community partners worldwide.
Inspiration for these partnerships comes from female athletes who embody strength, power, and the heart and soul of Nike. Throughout 2019, Nike will honor female champions and changemakers with the next phase of its “Just Do It” campaign, which has inspired millions of athletes to chase their crazy dreams. This year, Nike’s campaign shines a spotlight on women around the world who have broken barriers, revolutionized sport and helped level the playing field for all. Click here to view the newest chapters in Nike’s “Just Do It” film series, launching this year in key cities across the globe.
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, Nike’s earnings releases and other financial information are available at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @Nike.
For more information, including multi-media materials, please visit: http://news.nike.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005652/en/
Contact:
Media Contact Mark Rhodes (503) 532-8877
Investor Contact Nitesh Sharan (503) 532-2828
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
